Design of a Closed-loop Controller Based on the Bispectral Index (BIS) Effectiveness of the Smith Predictor

March 3, 2017 updated by: José Antonio Reboso Morales

Design of a Closed-loop Controller for the Administration of Propofol Based on the Bispectral Index (BIS). Effectiveness of the Smith Predictor and Comparison With Manual Control

The action of anesthetics such as propofol is not immediate after intravenous administration. Delay in pharmacodynamic effect of intravenous drugs is a commonly observed phenomenon in total intravenous anesthesia (TIVA). On the other hand, the measure of the clinical effect of propofol by EEG processed monitors like the bispectral index (BIS) also requires some processing time for the analysis of the recorded signal. Thus, the resulting BIS value provided by the monitor is affected by a delay. When a BIS based controller is used, the propofol infusion rates are defined using information of the BIS signal available. The delay in the BIS signal is an important issue as it can affect the performance of the controller. There are scarce contributions to address the delay in automatic administration of anesthesia.

Our proposal to deal with the dead time in the control action of the hypnotic component of anesthesia is a proportional-integral (PI) algorithm with a Smith predictor. The aim of this study is to evaluate and compare the feasibility and effectiveness of a closed-loop control using the Smith predictor versus manual control for propofol administration guided by the bispectral index (BIS) in adults patients. The objective is to show that a closed loop control can be a useful tool to provide safe and effective intravenous anesthesia and that the use of specific controller for delay rejection is a reliable strategy.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Modern medicine is focused on individualized treatment, including a personalized anesthesia administration. This implies to maintain the patient hypnotic state as closer as possible to a set target. TIVA with propofol and remifentanil has increased in popularity in recent years. Automatic systems can free the anesthesiologist of repetitive tasks. So, closed loop administration has been proposed to adjust propofol infusion rate without anesthesiologist intervention apart from supervising the procedure. A desired target of BIS is chosen by the clinician and feedback from the BIS monitor is used to adjust the rate of drug delivery continuously.

Closed loop control offers the opportunity of adjust the administration of anesthetics in an individualized way. It is also expected to overcome the individual pharmacokinetic and pharmacodynamic variability and to show a better adaptation to different levels of surgical stimulation. Closed loop control of propofol administration provides a greater stability in the level of hypnosis with a lower total dose of drug administered. Therefore, the recovery after anesthesia can be shorter. This can promote a better quality anesthetic care.

Previous studies with a PI controller showed in some patients a tendency to oscillate around a target value. This can be originated by the delay present in the system. One of the most known strategies in engineering to face the delay in closed loop is the Smith predictor. The purpose of this study is to evaluate and compare the feasibility and efficacy of a closed-loop control with a PI plus a Smith predictor algorithm versus manual control for propofol administration guided by the bispectral index (BIS) in adults patients.

Two groups of 25 adult patients scheduled for gynecological, urologic or abdominal surgery with an estimated duration > 30 minutes will be enrolled and randomized to one of the 2 groups. In the Manual control group (MC), the propofol infusion rate will be adjusted at the discretion of the anesthesiologist. In the PI+Smith group, propofol will be administered automatically by the closed-loop anesthesia system. The controller calculated automatically the error (target BIS - actual BIS) every 5 s and governed the infusion pump adapting the rate of propofol. The goal in both groups is to maintain BIS between 40 and 60 during maintenance phase of anesthesia. This is the recommended range of BIS for an adequate level of hypnosis during general anesthesia. Remifentanil will be infused for analgesia with the objective of to avoid an inadequate level of analgesia that could affect the stability of BIS signal.

Study Type

Interventional

Enrollment (Anticipated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Santa Cruz de Tenerife
      • La Laguna, Santa Cruz de Tenerife, Spain, 38320
        • Hospital Universitario de Canarias

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Ability to provide informed consent
  • 18 years of age or older
  • Classification of the American Society of Anesthesiologists (ASA) as I or II
  • Elective surgical procedures requiring general anesthesia with an estimated duration > 30 minutes

Exclusion Criteria:

  • Pregnant women,
  • Patients with neurological or psychiatric disorders
  • Patients taking any medication known to influence the EEG and subsequently the BIS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1: Manual control group
The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
Closed loop control for propofol administration guided by the BIS.
Manual control group: Propofol administration adjusted manually.
Experimental: 2: PI +Smith group
The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
Closed loop control for propofol administration guided by the BIS.
Manual control group: Propofol administration adjusted manually.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the performance of the 2 groups with the global score (GS).
Time Frame: During anesthesia maintenance, approximately 9 hours

Global score is a calculated parameter which gives an idea of the overall performance of a closed-loop system. It is calculated as the sum of MDAPE and wobble divided by the fraction of time BIS was within ±10 of the target. The target BIS chosen will be 50. The GS is calculated according the formula:

GS = (MDAPE + wobble)/ % of time with BIS between 40 and 60

During anesthesia maintenance, approximately 9 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The percentage of time with BIS values within +/10 % of target BIS.
Time Frame: During anesthesia maintenance, approximately 9 hours
Adequate depth of anaesthesia during surgical interventions
During anesthesia maintenance, approximately 9 hours
MDPE (median performance error)
Time Frame: During anesthesia maintenance, approximately 9 hours
The difference between the observed and target value of BIS.
During anesthesia maintenance, approximately 9 hours
MDAPE (median absolute performance error):
Time Frame: During anesthesia maintenance, approximately 9 hours
The median of the absolute values of performance errors.
During anesthesia maintenance, approximately 9 hours
Wobble
Time Frame: During anesthesia maintenance, approximately 9 hours
The median of the difference between individual PE and the MDPE for each participant, it measures the intra-individual variability of PE.
During anesthesia maintenance, approximately 9 hours
Time to eyes opening
Time Frame: 30 minutes after the end of the anesthesia
Time from discontinuation of the propofol and remifentanil infusions until the patient is able to open his eyes on command.
30 minutes after the end of the anesthesia
Time to tracheal extubation:
Time Frame: 30 minutes after the end of the anesthesia
Time from discontinuation of propofol infusion until endotracheal tube removal.
30 minutes after the end of the anesthesia
Total consumption of propofol and remifentanil during anesthesia maintenance
Time Frame: During anesthesia maintenance, approximately 9 hours
Propofol administered
During anesthesia maintenance, approximately 9 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 6, 2017

Primary Completion (Anticipated)

September 15, 2017

Study Completion (Anticipated)

September 15, 2017

Study Registration Dates

First Submitted

February 24, 2017

First Submitted That Met QC Criteria

March 3, 2017

First Posted (Actual)

March 8, 2017

Study Record Updates

Last Update Posted (Actual)

March 8, 2017

Last Update Submitted That Met QC Criteria

March 3, 2017

Last Verified

March 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on General Anesthesia

Clinical Trials on Propofol

Subscribe